Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective

Vineet Prajapati; Ankit Kumar Singh; Adarsh Kumar; Harshwardhan Singh; Prateek Pathak; Maria Grishina; Habibullah Khalilullah; Amita Verma; Pradeep Kumar

doi:10.1039/d4md00923a

journal article Jan 01, 2025

Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective

Vineet Prajapati Ankit Kumar Singh

Adarsh Kumar

Harshwardhan Singh Prateek Pathak

Maria Grishina

Habibullah Khalilullah

Amita Verma

Pradeep Kumar

RSC Medicinal Chemistry Vol. 16 No. 5 pp. 1923-1940 · Royal Society of Chemistry (RSC)

View at Publisher Save 10.1039/d4md00923a

Abstract

Normal and oncogenic RAS signalling pathway along with inhibitors.

Topics

No keywords indexed for this article. Browse by subject →

References

170

[1]

Visvader Nature (2011) 10.1038/nature09781

[2]

Brown Mol. Cancer (2023) 10.1158/1541-7786.mcr-23-0411

[3]

Ney Cancer Res. (2020) 10.1158/0008-5472.can-20-0916

[4]

Sheffels Genes (2021) 10.3390/genes12050662

[5]

Saxena Clin. Cancer Invest. J. (2008) 10.1080/07357900802087275

[6]

Adjei J. Natl. Cancer Inst. (2001) 10.1093/jnci/93.14.1062

[7]

Maertens Adv. Biol. Regul. (2014) 10.1016/j.jbior.2014.04.002

[8]

Stephen Cancer Cell (2014) 10.1016/j.ccr.2014.02.017

[9]

Simanshu Cancer Discovery (2022) 10.1158/2159-8290.cd-21-1494

[10]

Sheffels Small GTPases (2021) 10.1080/21541248.2019.1611168

[11]

Stalnecker Sci. Signaling (2020) 10.1126/scisignal.aay6013

[12]

Lim Cell Death Dis. (2019) 10.1038/s41419-019-2192-y

[13]

Quinlan Future Oncol. (2009) 10.2217/14796694.5.1.105

[14]

Cox Small GTPases (2010) 10.4161/sgtp.1.1.12178

[15]

Zeissig Trends Cancer (2023) 10.1016/j.trecan.2023.07.010

[16]

Asati Eur. J. Med. Chem. (2017) 10.1016/j.ejmech.2016.09.049

[17]

Kolch Biochem. J. (2023) 10.1042/bcj20220234

[18]

Cox Cancer Biol. Ther. (2002) 10.4161/cbt.306

[19]

Hyperactive Ras in developmental disorders and cancer

Suzanne Schubbert, Kevin Shannon, Gideon Bollag

Nature Reviews Cancer 2007 10.1038/nrc2109

[20]

Holderfield Cold Spring Harbor Perspect. Med. (2018) 10.1101/cshperspect.a031864

[21]

Ram RSC Med. Chem. (2023) 10.1039/d3md00145h

[22]

Parker Cold Spring Harbor Perspect. Med. (2018) 10.1101/cshperspect.a031427

[23]

Quah Pharmacol. Ther. (2016) 10.1016/j.pharmthera.2016.03.010

[24]

Johnson J. Biol. Chem. (2017) 10.1074/jbc.m117.778886

[25]

Pandey Arch. Biochem. Biophys. (2024)

[26]

Analysis of Binding Site Hot Spots on the Surface of Ras GTPase

Greg Buhrman, Casey O′Connor, Brandon Zerbe et al.

Journal of Molecular Biology 2011 10.1016/j.jmb.2011.09.011

[27]

Gorfe Structure (2008) 10.1016/j.str.2008.03.009

[28]

Harrison J. Mol. Biol. (2016) 10.1016/j.jmb.2016.10.017

[29]

Shima J. Biol. Chem. (2010) 10.1074/jbc.m110.125161

[30]

Buhrman J. Biol. Chem. (2011) 10.1074/jbc.m110.193854

[31]

Pandey Eur. J. Med. Chem. (2024) 10.1016/j.ejmech.2024.116771

[32]

Blocking Ras inhibition as an antitumor strategy

Nagore I. Marín-Ramos, Silvia Ortega-Gutiérrez, María L. López-Rodríguez

Seminars in Cancer Biology 2019 10.1016/j.semcancer.2018.01.017

[33]

Mattox Int. J. Mol. Sci. (2019) 10.3390/ijms21010141

[34]

F.-L.Statements , Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS (G12C) Inhibitor in Larger Patient Group At WCLC 2019

[35]

Blair Drugs (2021) 10.1007/s40265-021-01574-2

[36]

Hong N. Engl. J. Med. (2020) 10.1056/nejmoa1917239

[37]

Nakajima Clin. Cancer Res. (2022) 10.1158/1078-0432.ccr-21-3074

[38]

Lindsay Lung Cancer (2021) 10.1016/j.lungcan.2021.07.005

[39]

Dhillon Drugs (2023) 10.1007/s40265-023-01839-y

[40]

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel et al.

New England Journal of Medicine 2022 10.1056/nejmoa2204619

[41]

Ou J. Clin. Oncol. (2022) 10.1200/jco.21.02752

[42]

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Rona Yaeger, Jared Weiss, Meredith S. Pelster et al.

New England Journal of Medicine 2023 10.1056/nejmoa2212419

[43]

Badar Clin. Lymphoma, Myeloma Leuk. (2015) 10.1016/j.clml.2015.02.018

[44]

Bustinza-Linares Future Oncol. (2010) 10.2217/fon.10.71

[45]

Furuse Cancer Chemother. Pharmacol. (2018) 10.1007/s00280-018-3618-4

[46]

Riely J. Thorac. Oncol. (2011) 10.1097/jto.0b013e318223c099

[47]

Thomas Biol.: Targets Ther. (2007)

[48]

Lee Clin. Cancer Res. (2020) 10.1158/1078-0432.ccr-20-1246

[49]

Shipman Nat. Rev. Drug Discovery (2016) 10.1038/nrd.2016.40

[50]

Batrash Exp. Hematol. Oncol. (2023) 10.1186/s40164-023-00453-8

Showing 50 of 170 references

Metrics

3

Citations

170

References

Details

Published: Jan 01, 2025
Vol/Issue: 16(5)
Pages: 1923-1940
License: View

Authors

V

Vineet Prajapati

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India

A

Ankit Kumar Singh

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India; Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India

A

Adarsh Kumar

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India

H

Harshwardhan Singh

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India

P

Prateek Pathak

Department of Pharmaceutical Analysis, Quality Assurance and Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to be University), Hyderabad Campus, India

M

Maria Grishina

Laboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, Chelyabinsk, 454008, Russia

H

Habibullah Khalilullah

Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unayzah, 51911, Saudi Arabia

A

Amita Verma

Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India; Department of Allied Sciences (Chemistry), Graphic Era (Deemed to be University), Dehradun, 248002, India

P

Pradeep Kumar

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India

Funding

Science and Engineering Research Board Award: CRG/2022/008035

Cite This Article

Vineet Prajapati, Ankit Kumar Singh, Adarsh Kumar, et al. (2025). Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective. RSC Medicinal Chemistry, 16(5), 1923-1940. https://doi.org/10.1039/d4md00923a

Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective

You May Also Like